PL3581650T3 - Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego wytwarzania - Google Patents

Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego wytwarzania

Info

Publication number
PL3581650T3
PL3581650T3 PL19174517.3T PL19174517T PL3581650T3 PL 3581650 T3 PL3581650 T3 PL 3581650T3 PL 19174517 T PL19174517 T PL 19174517T PL 3581650 T3 PL3581650 T3 PL 3581650T3
Authority
PL
Poland
Prior art keywords
polypeptide
production
mutated factor
mutated
factor
Prior art date
Application number
PL19174517.3T
Other languages
English (en)
Polish (pl)
Inventor
Paolo Simioni
Original Assignee
Uniqure Biopharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3581650(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ITBO2008A000564A external-priority patent/IT1394177B1/it
Priority claimed from ITBO2009A000275A external-priority patent/IT1395980B1/it
Application filed by Uniqure Biopharma B.V. filed Critical Uniqure Biopharma B.V.
Publication of PL3581650T3 publication Critical patent/PL3581650T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL19174517.3T 2008-09-15 2009-09-15 Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego wytwarzania PL3581650T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITBO2008A000564A IT1394177B1 (it) 2008-09-15 2008-09-15 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
ITBO2009A000275A IT1395980B1 (it) 2009-05-06 2009-05-06 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione

Publications (1)

Publication Number Publication Date
PL3581650T3 true PL3581650T3 (pl) 2023-05-22

Family

ID=41397565

Family Applications (3)

Application Number Title Priority Date Filing Date
PL19174517.3T PL3581650T3 (pl) 2008-09-15 2009-09-15 Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego wytwarzania
PL09748260T PL2337849T3 (pl) 2008-09-15 2009-09-15 Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego otrzymywania
PL21200005.3T PL4032979T3 (pl) 2008-09-15 2009-09-15 Mutant polipeptydu czynnika ix, jego zastosowania i sposób jego otrzymywania

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL09748260T PL2337849T3 (pl) 2008-09-15 2009-09-15 Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego otrzymywania
PL21200005.3T PL4032979T3 (pl) 2008-09-15 2009-09-15 Mutant polipeptydu czynnika ix, jego zastosowania i sposób jego otrzymywania

Country Status (20)

Country Link
US (13) US9249405B2 (de)
EP (5) EP4219547A3 (de)
CA (1) CA2737094C (de)
CY (3) CY1125885T1 (de)
DK (2) DK3581650T3 (de)
ES (3) ES2687038T3 (de)
FI (5) FI3581650T3 (de)
FR (4) FR23C1028I1 (de)
HK (1) HK1244507A1 (de)
HR (2) HRP20230259T1 (de)
HU (6) HUE061345T2 (de)
LT (5) LT3581650T (de)
LU (1) LUC00311I2 (de)
NO (2) NO2023029I1 (de)
PL (3) PL3581650T3 (de)
PT (1) PT3581650T (de)
SI (1) SI3581650T1 (de)
SM (2) SMT202300084T1 (de)
TR (1) TR201813067T4 (de)
WO (1) WO2010029178A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4219547A3 (de) 2008-09-15 2023-10-18 uniQure biopharma B.V. Faktor-ix-polypeptidmutante, deren verwendungen und verfahren zu deren herstellung
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
SI3889173T1 (sl) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc. Optimiran gen dejavnika VIII
EP3160478A4 (de) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimiertes faktor-ix-gen
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
WO2016210170A1 (en) * 2015-06-23 2016-12-29 The Children's Hospital Of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
WO2017136358A1 (en) 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Optimized factor viii genes
PE20190401A1 (es) 2016-07-26 2019-03-13 Biomarin Pharm Inc Novedosas proteinas de la capside del virus adenoasociado
CN116355883A (zh) * 2016-10-14 2023-06-30 四川至善唯新生物科技有限公司 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用
CN110945127B (zh) 2017-05-22 2024-07-12 武田药品工业株式会社 用于血友病b的基因疗法的编码具有增加的表达的重组fix的病毒载体
PT3652326T (pt) 2017-07-10 2024-12-26 Uniqure Ip Bv Meios e métodos para terapia génica de aav em humanos
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
BR112020022722A8 (pt) 2018-05-09 2022-01-18 Biomarin Pharm Inc Genoma e seu uso, vetor, partícula, molécula de ácido nucleico isolada, ácido nucleico, composição, tratamento, método
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US20200069819A1 (en) 2018-05-14 2020-03-05 Biomarin Pharmaceutical Inc. Stable expression of aav vectors in juvenile subjects
SG11202101560QA (en) * 2018-08-20 2021-03-30 Ucl Business Ltd Factor ix encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) * 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
JP7578590B2 (ja) 2018-10-18 2024-11-06 インテリア セラピューティクス，インコーポレーテッド 第ｉｘ因子を発現するための組成物及び方法
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
US12173307B2 (en) 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
EP4362971A1 (de) * 2021-07-01 2024-05-08 CSL Behring Lengnau AG Subkutane verabreichung von faktor ix mit erhöhter sicherheit
WO2025022005A1 (en) * 2023-07-26 2025-01-30 Le Quellec Sandra Intranasal administration of factor ix polypeptides

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380848D1 (en) 1982-08-04 1989-12-21 Nat Res Dev Molecular cloning of the gene for human anti-haemophilic factor ix
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
US6227618B1 (en) 1996-02-23 2001-05-08 Schukra Usa, Inc. Cable attachment for a lumbar support
WO1997047737A1 (de) 1996-06-11 1997-12-18 Boehringer Mannheim Gmbh Rekombinante blutgerinnungsproteasen
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
ES2340008T3 (es) 1997-02-14 2010-05-27 American Red Cross Expresion de factor ix humano activo en tejido mamario de animales transgenicos.
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6610906B1 (en) 1999-06-09 2003-08-26 The Regents Of The University Of Michigan Nucleotide sequences for gene regulation and methods of use thereof
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
WO2001070763A1 (en) 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
AU2001269961A1 (en) 2000-07-06 2002-01-21 Guilford Pharmaceuticals Improved polymers and polymerization processes
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
KR20040039328A (ko) 2001-09-04 2004-05-10 메르크 파텐트 게엠베하 변형된 펙터 ⅸ
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20040009151A1 (en) 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
AU2003221733A1 (en) 2002-04-17 2003-11-03 University Of Florida Research Foundation, Inc. Improved raav vectors
CA2501295A1 (en) 2002-10-02 2004-04-15 Jack Nguyen Methods of generating and screening for proteases with altered specificity
DE602004030327D1 (de) 2003-05-21 2011-01-13 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
ATE469216T1 (de) 2004-08-17 2010-06-15 Csl Behring Gmbh Modifizierte vitamin-k-abhängige polypeptide
EP1627771B1 (de) 2004-08-19 2008-10-15 Gerd Bär Hubladebühne mit querverschiebbarem Verbindungsrohr
WO2006031226A1 (en) 2004-09-13 2006-03-23 Saint Louis University Region of factor ixa protease domain that interacts with factor viiia and methods therefor
EP1804839B1 (de) 2004-09-22 2012-03-14 St. Jude Children's Research Hospital Verbesserte expression von faktor-ix in gentherapie-vektoren
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP1828390B1 (de) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimäre vektoren
EP2433642B1 (de) 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modifizierte Proteasen zur Hemmung der Komplementaktivierung
WO2007059473A2 (en) 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
EP1791039A1 (de) 2005-11-25 2007-05-30 The Swatch Group Research and Development Ltd. Spiralfeder aus athermisches Glas für ein Uhrwerk und Herstellungsverfahren dafür
EP1969127B8 (de) 2005-12-21 2017-12-13 Aptevo BioTherapeutics LLC Verfahren zur herstellung biologisch wirksamer vitamin-k-abhängiger proteine mit rekombinanten verfahren
US7867484B2 (en) 2006-01-27 2011-01-11 University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
US7375084B2 (en) 2006-03-07 2008-05-20 Baxter International Inc. Highly phosphorylated and sulfated recombinant factor IX
US20080038224A1 (en) 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
CN101460055A (zh) 2006-04-07 2009-06-17 得克萨斯大学体系董事会 和腺伴随病毒-噬菌体颗粒相关的方法和组合物
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
US20070280906A1 (en) 2006-06-03 2007-12-06 Ognjen Petras Method to generate mirrored adenoassociated viral vectors
EP2423305A1 (de) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modifizierte Gerinnungsfaktor-IX-Polypeptide und deren Verwendung bei der Behandlung
EP2848253A1 (de) 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modifizierte Faktor-VIII- und Faktor-IX-Gene und Vektoren für Gentherapie
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
WO2008092643A2 (en) 2007-02-01 2008-08-07 Baxter International Inc. Improved fix-mutant proteins for hemophilia b treatment
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
WO2008127654A2 (en) 2007-04-11 2008-10-23 The University Of North Carolina At Chapel Hill Methods and compositions for intra-articular coagulation proteins
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
BRPI0705943A2 (pt) 2007-04-19 2008-12-09 Nautilus Biotech formulaÇÕes de dosagem oral de polipeptÍdeos resistentes À protease e usos das mesmas para tratamento
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
AU2008311973B2 (en) 2007-10-15 2013-10-03 Cangene Corporation Human Factor IX variants with an extended half life
CA2721683A1 (en) * 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
JP2011517950A (ja) 2008-04-16 2011-06-23 バイエル・ヘルスケア・エルエルシー 第ｉｘ因子の部位特異的修飾
CN102105582A (zh) 2008-04-21 2011-06-22 诺沃-诺迪斯克有限公司 高糖基化人凝血因子ix
EP2149603A1 (de) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und ihre Verwendung zur Behandlung von Blutungsstörungen
EP4219547A3 (de) 2008-09-15 2023-10-18 uniQure biopharma B.V. Faktor-ix-polypeptidmutante, deren verwendungen und verfahren zu deren herstellung
CN102596231B (zh) 2009-06-25 2016-01-20 北卡罗来纳-查佩尔山大学 嵌合因子ⅶ分子
EP2461821A4 (de) 2009-07-31 2013-07-03 Bayer Healthcare Llc Modifizierte faktor-ix-polypeptide und verwendungen davon
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
EP3513802B1 (de) 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vektor für gegen die leber gerichtete gentherapie von hämophilie, verfahren und verwendung davon
EP2881463A1 (de) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und/oder mit erhöhter F.IX-Gerinnungsaktivität und ihre Verwendung zur Behandlung von Blutungsstörungen
EP3160478A4 (de) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimiertes faktor-ix-gen
EP3270944B1 (de) 2015-03-17 2019-10-23 Vrije Universiteit Brussel Leberspezifische optimierte expressionssysteme für fviii und fix
CN115074366A (zh) 2015-04-16 2022-09-20 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
WO2016210170A1 (en) 2015-06-23 2016-12-29 The Children's Hospital Of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
EP3442597A1 (de) 2016-04-15 2019-02-20 The Trustees Of The University Of Pennsylvania Gentherapie zur behandlung von hämophilie b
KR102450833B1 (ko) 2016-04-15 2022-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 혈우병 a 치료용 유전자 요법
PT3652326T (pt) 2017-07-10 2024-12-26 Uniqure Ip Bv Meios e métodos para terapia génica de aav em humanos
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Also Published As

Publication number Publication date
FR23C1028I1 (fr) 2023-10-06
HRP20230259T1 (hr) 2023-04-28
FIC20240036I1 (fi) 2024-10-29
US20200190498A1 (en) 2020-06-18
CY2023016I2 (el) 2024-02-16
EP4032979B1 (de) 2024-05-01
HUE061345T2 (hu) 2023-06-28
ES2687038T3 (es) 2018-10-23
US9982248B2 (en) 2018-05-29
ES2940323T3 (es) 2023-05-05
HK1244507A1 (en) 2018-08-10
SMT201800468T1 (it) 2018-11-09
US20220090042A1 (en) 2022-03-24
LUC00311I2 (de) 2026-02-02
LTPA2023521I1 (de) 2023-08-25
EP2337849A1 (de) 2011-06-29
US10465180B2 (en) 2019-11-05
US20160122740A1 (en) 2016-05-05
PL4032979T3 (pl) 2024-09-30
CA2737094C (en) 2018-02-20
EP4032979A1 (de) 2022-07-27
FIC20250007I1 (fi) 2025-01-22
CA2737094F (en) 2010-03-18
NO2023029I1 (no) 2023-07-31
US20220002702A1 (en) 2022-01-06
HUS2400036I1 (hu) 2024-11-28
FIC20240037I1 (fi) 2024-10-30
US20210238573A1 (en) 2021-08-05
LT3581650T (lt) 2023-05-10
LTPA2025503I1 (de) 2025-02-10
SI3581650T1 (sl) 2023-06-30
US20200231958A1 (en) 2020-07-23
CY2023016I1 (el) 2024-02-16
LTPA2024530I1 (de) 2024-11-25
US20210214704A1 (en) 2021-07-15
ES2985035T3 (es) 2024-11-04
EP2337849B1 (de) 2018-06-13
FR25C1004I1 (fr) 2025-02-28
EP4032979C0 (de) 2024-05-01
CA2737094A1 (en) 2010-03-18
US20200199564A1 (en) 2020-06-25
FR24C1040I1 (fr) 2024-12-06
DK3581650T3 (da) 2023-03-13
WO2010029178A1 (en) 2010-03-18
FI3581650T3 (fi) 2023-03-23
EP4219547A2 (de) 2023-08-02
PL2337849T3 (pl) 2018-11-30
SMT202300084T1 (it) 2023-05-12
US9249405B2 (en) 2016-02-02
HUS2300024I1 (hu) 2023-08-28
US20170355973A1 (en) 2017-12-14
TR201813067T4 (tr) 2018-09-21
LTPA2024529I1 (de) 2024-12-10
HUS2500006I1 (hu) 2025-02-28
EP4219547A3 (de) 2023-10-18
EP3581650A2 (de) 2019-12-18
HRP20181442T1 (hr) 2018-12-14
CY2025002I1 (el) 2026-02-25
PT3581650T (pt) 2023-03-08
US20250179462A1 (en) 2025-06-05
EP3581650A3 (de) 2020-03-25
EP3581650B1 (de) 2022-12-28
FIC20230026I1 (fi) 2023-07-25
US20110244550A1 (en) 2011-10-06
HUE067487T2 (hu) 2024-10-28
NO2025007I1 (no) 2025-01-21
CY1125885T1 (el) 2024-02-16
USRE50288E1 (en) 2025-02-04
US20180258413A1 (en) 2018-09-13
FR24C1041I1 (fr) 2024-12-06
HUS2400037I1 (hu) 2024-11-28
EP3252157A1 (de) 2017-12-06
DK2337849T3 (en) 2018-10-01

Similar Documents

Publication Publication Date Title
PL3581650T3 (pl) Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego wytwarzania
IL288070B (en) Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
PL2640052T3 (pl) Terminal i sposób wyboru trybu kodowania
EP2584020A4 (de) Halosilikatleuchtstoffe, herstellungsverfahren und verwendung
PL2238047T3 (pl) Pojemnik złożony oraz sposób jego wytwarzania
BRPI0922248A2 (pt) eletrodo e método de produção do mesmo
SI2494039T1 (sl) Postopek reprogramiranja celic in njihova uporaba
PL3564361T3 (pl) Organoid wątroby, jego zastosowanie i sposoby hodowlane jego otrzymywania
SI3552619T1 (sl) Polipeptidi faktorja IX in načini njihove uporabe
DK3663399T3 (da) Modificerede factor IX-polypeptider og anvendelser deraf
PL2371019T3 (pl) Akumulator litowy i sposób jego wytwarzania
BR112013010725A2 (pt) método, e, composição
ME02952B (de) Wnt-antagonisten sowie behandlungs- und screening-verfahren dafür
HRP20182165T1 (hr) Postupak proizvodnje polipeptida ili virusa od interesa u kontinuiranoj staničnoj kulturi
HUE060371T2 (hu) Az L-ornitin-fenil-acetát és az elõállítására szolgáló eljárások
IL250606A0 (en) D2 antagonists, methods of synthesis and methods of use
EP2470565A4 (de) Modifizierte moleküle mit variablen domänen sowie herstellungs- und verwendungsverfahren dafür
PL2847799T3 (pl) Dachówka cementowa, układ z dachówek cementowych i sposób wytwarzania dachówki cementowej
FI20096186A0 (fi) Pinnoitettu puumateriaali, sen valmistusmenetelmä sekä käyttö
EP2760069A4 (de) Elektrodenmaterial, elektrode und herstellungsverfahren für elektrodenmaterial
HUP1000366D0 (en) Novel proteins, their production process and use tereof
PL2588232T3 (pl) Materiał katalityczny i sposób jego wytwarzania
EP2430170A4 (de) Erhöhte expression von transhydrogenasegenen und ihre verwendung in der ethanolherstellung
DK2324111T3 (da) Yderzone-tumorceller samt fremgangsmåde til fremstilling deraf samt anvendelse deraf
FI20106039A0 (fi) Kasvatusalusta, kasvatusalustan sisämateriaali sekä menetelmä kasvatusalustan valmistamiseksi